Alnylam Pharmaceuticals, Inc. (ALNY)

Alnylam Pharmaceuticals Revenue by Segment

Period Ending	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020
Amvuttra	1.09B	970.41M	859.20M	749.30M	651.30M	557.90M	451.20M	327.70M
Amvuttra Growth	66.62%	73.94%	90.43%	128.65%	232.98%	494.78%	1,690.48%	-
Collaboration	490.83M	510.15M	479.60M	849.70M	628.20M	546.20M	540.40M	142.20M
Collaboration Growth	-21.87%	-6.60%	-11.25%	497.54%	332.05%	305.19%	336.51%	24.08%
Givlaari	264.71M	255.85M	250.50M	233.60M	229.40M	219.20M	207.00M	198.60M
Givlaari Growth	15.39%	16.72%	21.01%	17.62%	23.40%	26.49%	24.03%	29.80%
Onpattro	233.09M	252.80M	275.70M	307.00M	321.30M	354.60M	397.80M	461.20M
Onpattro Growth	-27.45%	-28.71%	-30.69%	-33.43%	-38.58%	-36.41%	-30.70%	-16.04%
Oxlumo	166.46M	166.97M	156.10M	144.60M	128.20M	109.80M	100.90M	88.60M
Oxlumo Growth	29.85%	52.07%	54.71%	63.21%	61.66%	57.53%	54.99%	39.31%
Royalty	107.65M	91.79M	73.40M	59.90M	44.70M	40.60M	26.30M	19.10M
Royalty Growth	140.83%	126.08%	179.09%	213.61%	214.79%	401.23%	353.45%	430.56%

Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.